Citigroup
CLRB icon

Citigroup’s Cellectar Biosciences CLRB Stock Holding History

Citigroup’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19
Closed -$106 – 6119
2025
Q3 		$106 Buy
19
+18
+1,800% +$89 ﹤0.01% 5806
2025
Q2 		$7 Buy
+1
New +$9 ﹤0.01% 5591
2025
Q1 		– Sell
-22
Closed -$197 – 5642
2024
Q4 		$197 Buy
+22
New +$1.02K ﹤0.01% 5664
2015
Q1 		– Hold
0
– – – 7216
2014
Q4 		– Hold
0
– – – 7123

Other funds holding CLRB

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup's CLRB Position: Q4 2025 in Review

Citigroup sold out of Cellectar Biosciences (CLRB) in Q4 2025, closing a stake of 19 shares — an estimated $106 sold.

Citigroup first reported a position in CLRB in Q4 2024 and held it in 3 quarters. The position peaked at $197 in Q4 2024. 20 funds tracked by Wall St. Rank hold CLRB as of Q4 2025.

  • Citigroup reported no remaining Cellectar Biosciences position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 19 Cellectar Biosciences shares in Q4 2025, an estimated $106.
  • Citigroup first reported a position in Cellectar Biosciences in Q4 2024 and held it in 3 quarters.
  • Citigroup's Cellectar Biosciences position peaked at $197 in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.